BofA Securities Lowers Price Target on BridgeBio Pharma to $102 From $104, Maintains Buy Rating

Piper Sandler maintained an Overweight rating on BridgeBio Pharma (BBIO) and raised its price target to $120 from $115, citing growth potential in the biotech sector. The company's GF Value™ suggests it is 59.4% undervalued, but its GF Score™ indicates moderate performance with strong growth but weak financial strength. Insider selling activity totaled $4.58M over the last three months.

H.C. Wainwright reiterated a Buy rating and $120 price target for BridgeBio Pharma (BBIO) after positive Phase 3 trial data for encaleret. The stock trades near its fair value estimate, with a Strong Buy consensus and targets ranging from $80 to $156. BridgeBio also announced FDA acceptance of a New Drug Application for infigratinib, with a target action date in February 2027.

UBS initiated coverage of BridgeBio Pharma (BBIO) with a Buy rating and a $92 price target, citing underestimation of its lead drug's potential. UBS projects 2035 sales of $4.1B, higher than the $3.7B consensus. The firm's optimism is based on a 50-doctor survey, comparative data, and recent real-world evidence.

BridgeBio's NDA for oral infigratinib in achondroplasia received FDA Priority Review, with a PDUFA date of Feb 4, 2027. The treatment met primary and secondary endpoints in the PROPEL 3 trial, showing significant height and proportionality improvements. BridgeBio anticipates a U.S. launch if approved, according to the company.

BridgeBio Pharma, Inc. (BBIO) filed an SEC Form 8-K — Other Events. Exhibit 99.1 BridgeBio Announces FDA Acceptance and Priority Review of NDA for Oral Infigratinib for Children with Achondroplasia - Accepted for Priority Review with a PDUFA target action date of February 4, 2027; being granted Priority Review by the FDA underscores the significa

BridgeBio Pharma (BBIO) presented Phase 3 data for Encaleret in autosomal dominant hypocalcemia type 1, showing improved PTH levels and symptoms. The company also began a Phase 3 trial for chronic hypoparathyroidism. The FDA accepted its New Drug Application under Priority Review, with a target action date of May 8, 2027. BBIO shares closed at $65.35, up 0.48%.